Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study highlights scale of field trials for bovine TB vaccine
As many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission.
Researchers propose smaller, natural transmission experiments

New research has highlighted the cost and scale of field trials for bovine TB (bTB).

Writing in the journal eLife, researchers show that as many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission. They suggest that this scale and cost could be dramatically reduced by using smaller, less expensive experiments.

“We already know that the BCG vaccine has the potential to protect cattle from bovine TB infection,” explains first author Dr Andrew Conlan from the University of Cambridge’s department of veterinary medicine. “Our results highlight the enormous scale of trials that would be necessary to evaluate BCG alongside continuing testing in the field.

“Such trials would be hugely expensive, and it isn’t even clear whether enough farms could be recruited.”

The researchers propose a natural transmission experiment that involves housing a mixture of vaccinated and unvaccinated cattle with a number of infected cattle. They argue that such an experiment could show the efficacy of vaccination, using as little as 200 cattle.

In the UK, the bTB strategy is to ‘test and slaughter’ infected animals. Whilst the BCG vaccine does exist, it can cause some cattle to test positive falsely.

The BCG vaccine is currently banned in Europe. However, the European Union has stated that it would consider relaxing its laws if the UK government could show that a vaccine is effective on farms.

“If we could consider replacing test-and-slaughter with vaccination, then the economics becomes much more attractive particularly in lower income countries,” explained professor James Wood, head of Cambridge’s department of veterinary medicine.

“Then we would no longer need to carry out expensive testing, but could instead rely on passive surveillance through the slaughterhouses.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.